SCHEDULE 13G/A: Stonepine Capital Discloses 4.6% Passive Stake in CalciMedica, Inc.
Beneficial Ownership Disclosure
Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in CalciMedica, Inc.'s common stock as of March 31, 2025.
Summary
- Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico collectively reported beneficial ownership of 628,672 shares of CalciMedica, Inc. Common Stock.
- This aggregate ownership represents 4.6% of CalciMedica, Inc.'s outstanding Common Stock.
- The calculation of the percentage is based on 367,371 shares of Common Stock directly owned and 261,301 shares of Common Stock underlying warrants beneficially owned by the reporting persons.
- The total outstanding Common Stock of CalciMedica, Inc. was 13,481,917 shares as of March 21, 2025, as reported in the Issuer's Form 10-K for the fiscal year ended December 31, 2024.
- The reporting persons share both voting and dispositive power over all 628,672 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of CalciMedica, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news about the company.
Future Outlook
NA
Management Comments
- The reporting persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a standard disclosure of an institutional investor's passive ownership stake in a publicly traded biotechnology company, CalciMedica, Inc. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 2025-03-21 | Date of Common Stock outstanding count (13,481,917 shares) as reported in CalciMedica's Form 10-K for fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires the filing of this statement. |
| 2025-05-14 | Date of filing and signature date for the Schedule 13G Amendment No. 1. |
Keywords
CalciMedica Inc., Stonepine Capital Management, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, passive stake, equity ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.